Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TouCAHn: Atumelnant in Classic Congenital Adrenal Hyperplasia
NCT05907291Phase 2Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of atumelnant in congenital adrenal hyperplasia (CAH), sponsored by Crinetics Pharmaceuticals. Started Jul 2023; status: completed.
02
Drugs
atumelnant
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT05907291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907291.